Loading...

Orphazyme A/S

0CUM.LLSE
HealthcareMedical - Pharmaceuticals
$0.99
$-0.27(-21.25%)

Orphazyme A/S 0CUM.L Peers

See (0CUM.L) competitors and their performances in Stock Market.

Peer Comparison Table: Medical - Pharmaceuticals Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
0CUM.L$0.99-21.25%41.1K-0.05-$17.94N/A
0R0H.L$416.67-4.58%157B21.72$19.19+0.41%
0QZU.L$471.78-2.55%121.2B49.79$9.48N/A
0M3Q.L$144.78-4.01%64.5B33.21$4.36+1.15%
0R2M.L$544.09-4.73%57.8B7.74$70.31+0.30%
0HD2.L$284.73-0.38%37.1B-38.02-$7.49N/A
0HAV.L$107.96-1.27%30.8B26.05$4.15+0.90%
0RD1.L$515.44-0.09%30.2B-405.86-$1.27N/A
0JDM.L$143.13-6.09%24.8B25.85$5.54N/A
0K10.L$1,109.36-1.24%23.1B32.58$34.05N/A
Showing 1 to 10 of 100 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

0CUM.L vs 0R0H.L Comparison

0CUM.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 0CUM.L stands at 41.1K. In comparison, 0R0H.L has a market cap of 157B. Regarding current trading prices, 0CUM.L is priced at $0.99, while 0R0H.L trades at $416.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

0CUM.L currently has a P/E ratio of -0.05, whereas 0R0H.L's P/E ratio is 21.72. In terms of profitability, 0CUM.L's ROE is -0.31%, compared to 0R0H.L's ROE of +0.13%. Regarding short-term risk, 0CUM.L is less volatile compared to 0R0H.L. This indicates potentially lower risk in terms of short-term price fluctuations for 0CUM.L.

Stock Price Comparison

Loading...

Frequently Asked Questions